Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 5,600 shares of the company’s stock in a transaction that occurred on Monday, November 28th. The stock was bought at an average price of $10.61 per share, with a total value of $59,416.00. Following the purchase, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $32,561,570.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, November 23rd, Phillip Md Et Al Frost bought 4,300 shares of Opko Health stock. The shares were acquired at an average price of $10.09 per share, with a total value of $43,387.00.
  • On Tuesday, November 22nd, Phillip Md Et Al Frost bought 5,400 shares of Opko Health stock. The shares were acquired at an average price of $10.28 per share, with a total value of $55,512.00.
  • On Monday, November 21st, Phillip Md Et Al Frost bought 3,600 shares of Opko Health stock. The shares were acquired at an average price of $10.41 per share, with a total value of $37,476.00.
  • On Friday, November 18th, Phillip Md Et Al Frost bought 1,800 shares of Opko Health stock. The shares were acquired at an average price of $10.38 per share, with a total value of $18,684.00.
  • On Wednesday, November 16th, Phillip Md Et Al Frost bought 4,300 shares of Opko Health stock. The shares were acquired at an average price of $10.13 per share, with a total value of $43,559.00.
  • On Friday, November 11th, Phillip Md Et Al Frost bought 14,600 shares of Opko Health stock. The shares were acquired at an average price of $9.46 per share, with a total value of $138,116.00.
  • On Wednesday, November 9th, Phillip Md Et Al Frost bought 5,400 shares of Opko Health stock. The shares were acquired at an average price of $9.33 per share, with a total value of $50,382.00.
  • On Tuesday, November 8th, Phillip Md Et Al Frost bought 23,100 shares of Opko Health stock. The shares were acquired at an average price of $9.22 per share, with a total value of $212,982.00.
  • On Wednesday, November 2nd, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The shares were acquired at an average price of $9.48 per share, with a total value of $94,800.00.
  • On Tuesday, November 1st, Phillip Md Et Al Frost bought 10,000 shares of Opko Health stock. The shares were acquired at an average price of $9.49 per share, with a total value of $94,900.00.

Shares of Opko Health Inc. (NASDAQ:OPK) opened at 10.39 on Thursday. The firm’s market cap is $5.79 billion. Opko Health Inc. has a 12-month low of $7.12 and a 12-month high of $11.85. The company has a 50-day moving average of $9.76 and a 200 day moving average of $9.88.

Opko Health (NASDAQ:OPK) last issued its earnings results on Monday, November 7th. The company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). The firm earned $298 million during the quarter, compared to analysts’ expectations of $322 million. Opko Health had a negative return on equity of 0.49% and a negative net margin of 0.81%. Opko Health’s quarterly revenue was up 108.4% compared to the same quarter last year. During the same period last year, the business earned $0.25 earnings per share. Equities analysts predict that Opko Health Inc. will post ($0.08) EPS for the current year.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

COPYRIGHT VIOLATION WARNING: This piece of content was published by Daily Political and is the propert of of Daily Political. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be accessed at http://www.dailypolitical.com/2016/12/01/phillip-md-et-al-frost-acquires-5600-shares-of-opko-health-inc-opk-stock.html.

Several equities analysts have recently commented on OPK shares. JPMorgan Chase & Co. set a $14.00 price target on shares of Opko Health and gave the stock a “buy” rating in a research report on Tuesday, August 9th. Zacks Investment Research upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Tuesday, October 25th. Oppenheimer Holdings Inc. restated a “hold” rating on shares of Opko Health in a research report on Monday, October 10th. Jefferies Group restated a “hold” rating and set a $10.00 price target on shares of Opko Health in a research report on Monday, October 10th. Finally, TheStreet lowered shares of Opko Health from a “hold” rating to a “sell” rating in a research report on Wednesday, November 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. Opko Health currently has an average rating of “Hold” and an average target price of $13.17.

A number of hedge funds and other institutional investors have recently modified their holdings of OPK. Whalerock Point Partners LLC purchased a new position in shares of Opko Health during the third quarter valued at approximately $2,100,000. Piedmont Investment Advisors LLC purchased a new position in shares of Opko Health during the third quarter valued at approximately $622,000. Price T Rowe Associates Inc. MD boosted its position in shares of Opko Health by 3.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 947,871 shares of the company’s stock valued at $10,038,000 after buying an additional 28,700 shares during the period. Finally, LPL Financial LLC boosted its position in shares of Opko Health by 3.9% in the third quarter. LPL Financial LLC now owns 13,374 shares of the company’s stock valued at $142,000 after buying an additional 504 shares during the period. 22.27% of the stock is owned by hedge funds and other institutional investors.

About Opko Health

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NASDAQ:OPK

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.